Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 7;6(4):e299-e303.
doi: 10.1055/a-1920-6224. eCollection 2022 Oct.

Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome

Tess Van Meerhaeghe  1 , Alexandre Cez  2 , Karine Dahan  2 , Emmanuel Esteve  2 , Ismail Elalamy  3   4   5   6 , Jean Jacques Boffa  2   5 , Eleonore Ponlot  7
Affiliations

Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome

Tess Van Meerhaeghe et al. TH Open. .

Abstract

Background Nephrotic syndrome (NS) is associated with an increased risk of thromboembolic events (TEs), due to hemostatic derangements. The use of direct oral anticoagulants (DOACs) in the prevention of TE has not been studied intensively in patients suffering from NS. Methods The method included retrospective analysis of consecutive incident patients with NS due to glomerular disease, receiving apixaban for thromboprophylaxis. It is an uncontrolled, single-center study. Results We identified 27 patients treated with apixaban for the prevention of TEs, in the context of NS. During follow-up, apixaban minimal blood concentration (trough level; Cmin) and maximum blood concentration (Cmax) levels were measured. The mean duration of the anticoagulant treatment was 153 days (±132). Patients were followed for a mean of 14.7 months (±8.4) since the introduction of apixaban. Three patients had a TE at the time of NS diagnosis. Two patients had pulmonary embolism (PE) and one patient presented a stroke in a lupus membranous nephropathy context. One patient developed PE approximately 2 months after the introduction of apixaban treatment. No minor or major bleeding events were noticed. Conclusion The present study shows that patients, suffering from severe NS under anticoagulant therapy with apixaban had a reduced risk of venous and arterial TEs compared with patients previously described in the literature, without increased risk of bleeding.

Keywords: anticoagulation; direct oral anticoagulants; hypoalbuminemia; nephrotic syndrome; thromboembolic event; thromboprophylaxis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests None declared.

Figures

Fig. 1
Fig. 1
Apixaban trough Cmin and Cmax levels (2 hours after ingestion) are shown for patients on Apixaban 5 mg bid.
Fig. 2
Fig. 2
Apixaban trough Cmin and Cmax levels (2 hours after ingestion) are shown for patients on Apixaban 2.5 mg bid.
See this image and copyright information in PMC

References

    1. Kerlin B A, Ayoob R, Smoyer W E. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7(03):513–520. - PMC - PubMed
    1. Barbour S J, Greenwald A, Djurdjev O. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81(02):190–195. - PubMed
    1. Gyamlani G, Molnar M Z, Lu J L, Sumida K, Kalantar-Zadeh K, Kovesdy C P. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. 2017;32(01):157–164. - PMC - PubMed
    1. Ismail G, Mircescu G, Ditoiu A V, Tacu B D, Jurubita R, Harza M. Risk factors for predicting venous thromboembolism in patients with nephrotic syndrome: focus on haemostasis-related parameters. Int Urol Nephrol. 2014;46(04):787–792. - PubMed
    1. Mahmoodi B K, ten Kate M K, Waanders F. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117(02):224–230. - PubMed